annb0t
Top 20
Immutep Limited
Media Release
Overall responserate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002
all-comerPD-L1Phase II trial in1stline non-small cell lung cancer (1L NSCLC)
ORR improved across all PD-L1 status groupsby central assessmentcompared with data
reported at ASCO 2022,including 48.3%, 44.7%, 55.0%, and 31.3% ORR in patients
with PD-L1 TPS of>1%,1-49%, >50%, and <1%, respectively
Interim median Duration of Response (DoR) of 21.6 months,compares favourably to histo...
>>> Read more: Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
Media Release
Overall responserate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002
all-comerPD-L1Phase II trial in1stline non-small cell lung cancer (1L NSCLC)
ORR improved across all PD-L1 status groupsby central assessmentcompared with data
reported at ASCO 2022,including 48.3%, 44.7%, 55.0%, and 31.3% ORR in patients
with PD-L1 TPS of>1%,1-49%, >50%, and <1%, respectively
Interim median Duration of Response (DoR) of 21.6 months,compares favourably to histo...
>>> Read more: Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
